Vireo Growth (FRA:K95) ROIC %: 10.42% (As of Mar. 2026)


FRA:K95 Vireo Growth Inc FRA:K95
44 GF Score
Price €8.42
GF Value €7.54
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vireo Growth ROIC %?

Vireo Growth FRA:K95 -5.39% 44 ROIC % is 10.42% as of Mar. 2026. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Vireo Growth's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 10.42%.

As of today (2026-06-25), Vireo Growth's WACC % is 2.70%. Vireo Growth's ROIC % is 4.61% (calculated using TTM income statement data). Vireo Growth generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Vireo Growth  (FRA:K95) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Vireo Growth's WACC % is 2.70%. Vireo Growth's ROIC % is 4.61% (calculated using TTM income statement data). Vireo Growth generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Vireo Growth ROIC % Related Terms


Vireo Growth ROIC % Historical Data

* Premium members only.

The historical data trend for Vireo Growth's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vireo Growth ROIC % Chart

Vireo Growth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.82 -5.37 6.21 9.59 2.34

Vireo Growth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.04 2.94 1.15 1.69 10.42

FRA:K95 vs ZTS: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's ROIC % distribution charts can be found below:

* The bar in red indicates where Vireo Growth's ROIC % falls into.


FRA:K95
44GF Score
Vireo Growth Inc FRA:K95
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vireo Growth ROIC % Calculation

Vireo Growth's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=8.677 * ( 1 - 0% )/( (169.852 + 570.795)/ 2 )
=8.677/370.3235
=2.34 %

where

Vireo Growth's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=61.24 * ( 1 - 0% )/( (570.795 + 604.203)/ 2 )
=61.24/587.499
=10.42 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=803.412 - 162.447 - ( 106.741 - max(0, 186.667 - 223.429+106.741))
=604.203

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 10.42% mean?
Vireo Growth (FRA:K95) has a ROIC % of 10.42% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Vireo Growth and its competitors.
Is Vireo Growth's ROIC % too high?
Vireo Growth's current ROIC % is 10.42%. The Drug Manufacturers industry median ROIC % is 4.44. Vireo Growth's value of 10.42% is 134.7% above this industry median. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's ROIC % compare to ZTS?
Vireo Growth's ROIC % of 10.42% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.44. Vireo Growth's value of 10.42% is 134.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current ROIC % of 10.42% is 134.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current ROIC % is 10.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current ROIC % is 10.42% and 134.7% above the Drug Manufacturers industry median of 4.44. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current ROIC % is 10.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vireo Growth (FRA:K95) Overvalued in 2026?

Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued. The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54. GuruFocus considers Vireo Growth to be Modestly Overvalued.

Key valuation signals for FRA:K95:

  • ROIC %: 10.42%
  • GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
  • GF Score™: 44/100 with 6 warning signs
  • Industry Position: 134.7% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vireo Growth Business Description

Other Exchanges VREOD:USAVREO:Canada
Address 207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score

Get the complete analysis for FRA:K95

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.42
Price
€7.54
GF Value